Albireo to Report First Quarter 2020 Financial Results on May 7
30 April 2020 - 3:47PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that management will host a conference
call and live audio webcast at 10:00 a.m. ET on May 7,
2020, to provide a business update and review the company’s
financial results for the first quarter ended March 31, 2019.
To access the live conference call by phone, please
dial 877-407-0792 (domestic) or 201-689-8263 (international),
and provide the access code 13699920. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website, http://ir.albireopharma.com/. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for 3 months following the event.
About Albireo Albireo Pharma
is a clinical-stage biopharmaceutical company focused on the
development of novel bile acid modulators to treat orphan pediatric
liver diseases, and other liver and gastrointestinal diseases and
disorders. Albireo’s lead product candidate, odevixibat, is being
developed to treat rare pediatric cholestatic liver diseases and is
in Phase 3 development in its initial target indication,
progressive familial intrahepatic cholestasis (PFIC). Albireo’s
clinical pipeline also includes two Phase 2 product candidates.
Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in
Japan for the treatment of chronic constipation, elobixibat is the
first ileal bile acid transporter (IBAT) inhibitor approved
anywhere in the world.
Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Mass., and its key operating
subsidiary is located in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2019 Best Places to Work in
Massachusetts. For more information on Albireo, please visit
www.albireopharma.com.
Investor Contact: Hans Vitzthum,
LifeSci Advisors, LLC.,
212-915-2568
Media Contact: Heather Anderson, 6 Degrees,
980-938-0260, handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024